$15.57
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
Novocure to Report Second Quarter 2026 Financial Results
Overview
52-week range
$9.82
$19
61% of range
Avg surprise (last 2)
+20.9%
Avg reaction (last 2)
-9.8%
50% positive
Latest IV / EM
85%
EM ±19.4% · $16 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.62 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.33 | — | — | — | — | financials |
| Thu Jul 24, 2025 | Jun/2025 | $-0.36 | $-0.39 | +7.7% | — | -24.0% | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $-0.31 | $-0.47 | +34.0% | — | +4.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.28 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.31 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.36 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.54 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 23, 2026 | Jun/2026 | BMO | -$0.30 | -$0.36 | +16.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $174M | — | $167M | $159M | $155M | — | $155M | $150M |
| Cost of revenue | $39M | — | $45M | $41M | $39M | — | $35M | $35M |
| Gross profit | $135M | — | $122M | $117M | $116M | — | $120M | $116M |
| Operating income | $-67M | — | $-36M | $-40M | $-38M | — | $-32M | $-34M |
| Net income | $-71M | — | $-37M | $-40M | $-34M | — | $-31M | $-33M |
| EPS (diluted) | $-0.62 | — | $-0.33 | $-0.36 | $-0.31 | — | $-0.28 | $-0.31 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $88M | $94M | $342M | $150M | $127M | $164M | $185M | $165M |
| Inventory | $43M | $41M | $39M | $40M | $39M | $35M | $39M | $40M |
| Total current assets | $632M | $647M | $1.20B | $1.08B | $1.09B | $1.11B | $1.10B | $1.09B |
| Total assets | $788M | $804M | $1.36B | $1.25B | $1.25B | $1.24B | $1.22B | $1.21B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $457M | $464M | $1.02B | $896M | $887M | $881M | $861M | $850M |
| Total equity | $331M | $340M | $341M | $349M | $362M | $360M | $361M | $362M |